Related Experiment Video
Updated: Jun 30, 2025

Electroretinogram Recording for Infants and Children under Anesthesia to Achieve Optimal Dark Adaptation and International Standards
Published on: September 3, 2020
Efficacy of Melatonin as a Sleep Inducer in EEG Procedures in the Pediatric Population: A Cross-Sectional Study
Saja Tahir1, Kate Flynn2, Mohamed O E Babiker1
1Department of Pediatrics, Al Jalila Children's Speciality Hospital, Dubai, ARE.
Insights
Melatonin effectively induces sleep in most children undergoing electroencephalogram (EEG) procedures. However, success rates are lower for pediatric patients with neurobehavioral disorders.
Area of Science:
- Pediatric Neurology
- Sleep Medicine
- Clinical Pharmacology
Background:
- Melatonin is a common alternative to sleep deprivation for inducing sleep in pediatric patients before EEG.
- Understanding the efficacy of current melatonin dosages is crucial for optimizing pediatric EEG procedures.
Purpose of the Study:
- To evaluate the effectiveness of melatonin in inducing sleep for pediatric electroencephalogram (EEG) examinations.
- To determine the time required for sleep induction and identify factors influencing success rates.
Main Methods:
- A retrospective cross-sectional study analyzed 126 pediatric patients who received melatonin prior to EEG.
- Doses varied by age: 2-6 mg for 1-3 years, 10 mg for older children.
- Data collected included sleep success rate, time to sleep, gender, neurobehavioral disorders, and antiepileptic drug (AED) use.
Main Results:
- Melatonin successfully induced sleep in 84.9% of patients, with a mean sleep induction time of 24 minutes.
- Patients with neurobehavioral disorders had a significantly lower success rate (p=0.003).
- No significant differences in success rates were observed based on gender or AED use.
Conclusions:
- Melatonin is a highly effective sleep-inducing agent for pediatric EEG procedures.
- Consideration of melatonin is recommended for most pediatric patients requiring EEG.
- Lower efficacy should be anticipated in pediatric patients with neurobehavioral disorders.
Abstract:
Introduction Melatonin has been used as an alternative to sleep deprivation for EEG sleep induction in the pediatric population. Our study aims to describe the efficacy of the currently used doses of melatonin for sleep induction among the pediatric age group. Methods A retrospective cross-sectional study included all patients who underwent an EEG after receiving melatonin over the period of one year. A total of 126 patients have been included in the study. Patients aged one year to three years received oral melatonin in doses between 2 mg and 6 mg. Patients in the age of three years and above received 10 mg of melatonin. Patients' success rate in achieving sleep and the exact time required for the patients to fall asleep were obtained using the readings of their EEG. The percentage of patients who have achieved sleep and the time required for those patients to sleep were calculated and correlated with the patient's gender, the presence of any associated neurobehavioral disorders, and their use of antiepileptic drugs (AED). Results Successful sleep was achieved in 84.9% (n:107) of the patients, with a mean time of 24 minutes to fall asleep (SD = 14.36). Patients with neurobehavioral disorders were 20% less likely to fall asleep when compared to other patients without neurobehavioral disorders (p: 0.003). However, there was not a statistically significant difference among different genders and among patients who received AED. Conclusion Melatonin is an effective sleep inducer for patients undergoing EEG procedures. It should be considered in the majority of patients. However, in patients with neurobehavioral disorders, a lower success rate is expected.
Related Concept Videos
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

